Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,fiftyDayAverage,fiftyDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,IBXXF,12913867.0,1042590016,,,-1812756,,-1812756,1696101,-413920,-2290308,-2290308,,-21926,,,,0,192160,2482468,606080,477552,,-1812756,-1812756,1205137.0,12913867.0,145227.0,14119004.0,51322126.0,38320.0,-40009548.0,1536.0,1601289.0,13200547.0,900853.0,1601289.0,685017.0,13433987.0,65514.0,288301.0,-93020,-3930,-158525,6127752,6922933,4436810,-42812,-1644199,180287,-33000,-636658,114289,-3930,12533134.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.0025,1630330208,0.0,0.0025,0.0025,0.0025,40,0,IMAGION BIOSYSTEMS LIMITED,PRE,us_market,0.0,0.0025 - 0.0025,0.0025,finmb_117476770,Other OTC,Imagion Biosystems Limited,AUD,15627,223,0.0,0.0,0.0025 - 0.48,-0.4775,-0.9947917,0.0025,0.48,-0.97295266,0.11979859,-0.117298596,-0.97913164,0.092430554,-0.08993056,2606475,15,America/New_York,EDT,-14400000,False,False,3.44,,,0.48,0.0025,0.0924,0.1198,15.63k,223,1.04B,,872.07M,9.74%,0.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-198.89%,-194.99%,-34.61%,-67.52%,2.7M,0.00,191.10%,-163.81k,-5.19M,-5.36M,,,13.2M,0.01,660.98k,5.12,14.91,,-4.62M,-3.05M,Value,92121,Healthcare,"Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.",San Diego,855 564 5264,CA,1609372800,United States,http://imagionbiosystems.com,86400,10355 Science Center Drive,Diagnostics & Research,Suite 210
t-1,IBXXF,12913867.0,1042590016,,,-1812756,,-1812756,1696101,-413920,-2290308,-2290308,,-21926,,,,0,192160,2482468,606080,477552,,-1812756,-1812756,1205137.0,12913867.0,145227.0,14119004.0,51322126.0,38320.0,-40009548.0,1536.0,1601289.0,13200547.0,900853.0,1601289.0,685017.0,13433987.0,65514.0,288301.0,-93020,-3930,-158525,6127752,6922933,4436810,-42812,-1644199,180287,-33000,-636658,114289,-3930,12533134.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.0025,1630330208,0.0,0.0025,0.0025,0.0025,40,0,IMAGION BIOSYSTEMS LIMITED,PRE,us_market,0.0,0.0025 - 0.0025,0.0025,finmb_117476770,Other OTC,Imagion Biosystems Limited,AUD,15627,223,0.0,0.0,0.0025 - 0.48,-0.4775,-0.9947917,0.0025,0.48,-0.97295266,0.11979859,-0.117298596,-0.97913164,0.092430554,-0.08993056,2606475,15,America/New_York,EDT,-14400000,False,False,3.44,,,0.48,0.0025,0.0924,0.1198,15.63k,223,1.04B,,872.07M,9.74%,0.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-198.89%,-194.99%,-34.61%,-67.52%,2.7M,0.00,191.10%,-163.81k,-5.19M,-5.36M,,,13.2M,0.01,660.98k,5.12,14.91,,-4.62M,-3.05M,Value,92121,Healthcare,"Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.",San Diego,855 564 5264,CA,1609372800,United States,http://imagionbiosystems.com,86400,10355 Science Center Drive,Diagnostics & Research,Suite 210
t-2,IBXXF,3546427.0,1042590016,,,-869248,,-869248,671144,332016,-339128,-339128,,-21926,,,,0,1156322,1495450,824306,-530120,,-869248,-869248,2194650.0,3546427.0,34988.0,5741077.0,39132707.0,342938.0,-36384037.0,,797757.0,4326926.0,1743169.0,797757.0,1062835.0,4678242.0,8378.0,1283727.0,0,-3930,35120,1132617,1130879,462607,-2665,-667346,180287,-33000,-33381,201903,-3930,2935073.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.0025,1630330208,0.0,0.0025,0.0025,0.0025,40,0,IMAGION BIOSYSTEMS LIMITED,PRE,us_market,0.0,0.0025 - 0.0025,0.0025,finmb_117476770,Other OTC,Imagion Biosystems Limited,AUD,15627,223,0.0,0.0,0.0025 - 0.48,-0.4775,-0.9947917,0.0025,0.48,-0.97295266,0.11979859,-0.117298596,-0.97913164,0.092430554,-0.08993056,2606475,15,America/New_York,EDT,-14400000,False,False,3.44,,,0.48,0.0025,0.0924,0.1198,15.63k,223,1.04B,,872.07M,9.74%,0.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-198.89%,-194.99%,-34.61%,-67.52%,2.7M,0.00,191.10%,-163.81k,-5.19M,-5.36M,,,13.2M,0.01,660.98k,5.12,14.91,,-4.62M,-3.05M,Value,92121,Healthcare,"Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.",San Diego,855 564 5264,CA,1609372800,United States,http://imagionbiosystems.com,86400,10355 Science Center Drive,Diagnostics & Research,Suite 210
t-3,IBXXF,3546427.0,1042590016,,,-869248,,-869248,671144,332016,-339128,-339128,,-21926,,,,0,1156322,1495450,824306,-530120,,-869248,-869248,2194650.0,3546427.0,34988.0,5741077.0,39132707.0,342938.0,-36384037.0,,797757.0,4326926.0,1743169.0,797757.0,1062835.0,4678242.0,8378.0,1283727.0,0,-3930,35120,1132617,1130879,462607,-2665,-667346,180287,-33000,-33381,201903,-3930,2935073.0,en-US,US,EQUITY,False,Delayed Quote,USD,4,PNK,0.0025,1630330208,0.0,0.0025,0.0025,0.0025,40,0,IMAGION BIOSYSTEMS LIMITED,PRE,us_market,0.0,0.0025 - 0.0025,0.0025,finmb_117476770,Other OTC,Imagion Biosystems Limited,AUD,15627,223,0.0,0.0,0.0025 - 0.48,-0.4775,-0.9947917,0.0025,0.48,-0.97295266,0.11979859,-0.117298596,-0.97913164,0.092430554,-0.08993056,2606475,15,America/New_York,EDT,-14400000,False,False,3.44,,,0.48,0.0025,0.0924,0.1198,15.63k,223,1.04B,,872.07M,9.74%,0.01%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-198.89%,-194.99%,-34.61%,-67.52%,2.7M,0.00,191.10%,-163.81k,-5.19M,-5.36M,,,13.2M,0.01,660.98k,5.12,14.91,,-4.62M,-3.05M,Value,92121,Healthcare,"Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.",San Diego,855 564 5264,CA,1609372800,United States,http://imagionbiosystems.com,86400,10355 Science Center Drive,Diagnostics & Research,Suite 210
